United States· US:68083-707_8b45ebae-92d6-4a3b-a559-115c66a8352a
Epoprostenol
A epoprostenol product containing epoprostenol, registered in United States by Gland Pharma Limited. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Epoprostenol is registered in 14 of 19 countries.
Countries holding a registration under ATC B01AC09 (epoprostenol), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Epoprostenol · ATC B01AC09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- EPOPROSTENOL
- Manufacturer
- Gland Pharma Limited
- Country
- United States (US)
- ATC code
- B01AC09
- ATC class
- Epoprostenol
- Defined daily dose
- 38 mcg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1168083-707-01
- ndc1168083707011 VIAL in 1 CARTON (68083-707-01) / 10 mL in 1 VIAL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
402 interactions on record for epoprostenol.
Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Epoprostenol · interactions on record
402 records
- 34 severe
- 269 moderate
- 4 minor
- 95 info
Most severe, free to view
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
- DanaparoidB01AB09severe
- TinzaparinB01AB10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Epoprostenol in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsEpoprostenol SUN 0,5 mg, poeder voor oplossing voor infusieSun Pharmaceutical Industries Europe B.V.
- United KingdomEpoprostenol 1.5mg powder (pH12) for solution for infusion vialsSun Pharma UK Ltd
- CzechiaFLOLANGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumEpoprostenol Sandoz 0,5 mgSandoz
- SpainEPOPROSTENOL NORMON 1,5 MG POLVO PARA SOLUCION PARA PERFUSIONLaboratorios Normon S.A.
- CanadaCARIPULJANSSEN INC
- IrelandFlolan 0.5 mg powder and solvent for solution for infusionGlaxoSmithKline (Ireland) Limited
- NorwayEpoprostenol sunSun Pharmaceutical
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Austria · Flolan
- Belgium · Flolan, Veletri
- Czechia · Flolan, Veletri
- Germany · Veletri
- Denmark · Flolan
- Spain · Epoprostenol Normon, Epoprostenol Sun
- France · Epoprostenol Panpharma, Veletri
- United Kingdom (Northern Ireland) · Epoprostenol Mercury Pharmaceuticals Ltd, Epoprostenol Sodium Hexal
- Greece · Veletri
- Hungary · Veletri
- Ireland · Flolan, Veletri
- Italy · Caripul, Flolan
- Luxembourg · Flolan, Veletri
- Netherlands · Epoprostenol Sun, Epoprostenol Sun Pharmaceutical Industries Europe
- Poland · Veletri
- Portugal · Epoprostenol Normon, Veletri
- Slovakia · Veletri
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9c23a8b0-b742-43a0-bb7b-22226a7d9acd GET /v1/drugs/9c23a8b0-b742-43a0-bb7b-22226a7d9acd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": ".5",
"substance": "EPOPROSTENOL",
"productndc": "68083-707",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/10mL",
"application_number": "ANDA219237",
"marketing_category": "ANDA"
}See everything about epoprostenol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.